Small airways disease in bronchial asthma and the role of extrafine inhaled formulations in clinical practice. Resolution of the Expert Council
Small airways disease (SAD) in bronchial asthma (BA) has been characterized in detail, yet it is rarely assessed in routine care and is not reflected in current stepwise treatment algorithms. In the ATLANTIS (Assessment of Small Airways Involvement in Asthma) study, signs of SAD were detectable in 91% of patients with...